Bortezomib, thalidomide, and dexamethasone versus thalidomide and dexamethasone for response rates in multiple myeloma patients: a retrospective study by Juan M. Cano-Calderón, Juan F. Zazueta-Pozos, Adán G. Gallardo-Rodríguez, Carlos Martínez-Murillo, Irma Olarte-Carrillo, Adolfo Martínez-Tovar, Christian O. Ramos-Peñafiel

Subjects: “…Multiple myeloma. Bortezomib. Thalidomide. Acute phase response. Survival.…”
Get full text

Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis by Yin-Che Wang, Cheng-Hsien Lin, Yu-Chen Su, Chieh-Lin Jerry Teng

Get full text

Synthesis, <i>In Vitro</i> and <i>In Silico</i> Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents by Wael Shehta, Norah A. Alsaiari, Basant Farag, Marwa M. Abdel-Aziz, Shaker Youssif, Sherin M Elfeky, Samar El-Kalyoubi, Nermine A. Osman

Get full text

Carvacrol attenuated haloperidol-induced Parkinson’s disease via TNF/NFκβ-NLRP3-mediated pyroptosis by Faisal Albaqami, Khawaja Waqas Ahmad, Fawad Ali Shah

Subjects: Get full text

Real-world outcomes of maintenance therapy post-autologous stem cell transplantation in newly diagnosed multiple myeloma by Ka-Won Kang, Dae Sik Kim, Se Ryeon Lee, Mi Hwa Heo, Hyeon-Seok Eom, Jongheon Jung, Ji Hyun Lee, Sung-Hyun Kim, Youngil Koh, Chang-Ki Min, Seung Shin Lee, Sung-Nam Lim, Ho-Young Yhim, Myung-won Lee, Je-Jung Lee, Sung-Hoon Jung, Soo-Mee Bang, Kihyun Kim, the Korean Multiple Myeloma Working party [KMMWP]

Subjects: Get full text

Use of Minimal Residual Disease Status to Reduce Uncertainty in Estimating Long-term Survival Outcomes for Newly Diagnosed Multiple Myeloma Patients by Naomi van Hest, Peter Morten, Keith Stubbs, Nicola Trevor

“…**Methods:** Standard and response-based PSMs, estimating patient life-years (LYs) over a lifetime horizon, were developed for NDMM patients treated with bortezomib, thalidomide, and dexamethasone (BTd) with or without daratumumab as induction and consolidation therapy. …”
Get full text